The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

NCT03455842 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Seropositive RA

Interventions

BIOLOGICAL: BCD-089, 162 mg, s/c, qw
BIOLOGICAL: BCD-089, 162 mg, s/c, q2w
DRUG: placebo

Sponsor

Biocad